MKT CAP Approx $60m SOI around 190m plus around 3.3m options - performance, unlisted
Solid area of serious congestion, where the price is now, after the machinations of potential removal of the surgery from payment codes in Medicare in the US, then abandonment of those changes.
Volume has been extreme over this period.
RSI AND MACD look like they are very high, so not conducive to an entry.
However, as with all analysis, the fundamental blends in here after todays Sales Update from the US, which despite 2 months of severely restricted business due to uncertainty over Medicare reimbursement, sales have been 65% higher then the PCP. One has to wonder how much they would have been up without that unnecessary and unsettling period.
Arguably the most advanced device in this sector, and also has a second significant potential in the area of Macular degeneration through 2RT
I like this one over the short term but also over the next 12 to 18 months. It also has to be a takeover target IMO.
